000230.KO Ildong Holdings Co Ltd
- Market cap
- KRW 65.2B
- P/E
- 3.0x
- P/B
- 0.37x
- ROE
- 1.6%
- Dividend yield
- 0.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 000230.KO undervalued?
Graham numberThe Graham number of Ildong Holdings Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ildong Holdings Co Ltd fundamental analysis
No fundamental analysis for Ildong Holdings Co Ltd yet.
Ildong Holdings Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ildong Holdings Co Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluron…
Full company profileIldong Holdings Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ildong Holdings Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 40.8B | 41.1B | 47.1B | 292B | 596B | 592B | 676B | 638B | 635B | 591B | 606B |
| Gross Profit | 17.7B | 18.2B | 20.0B | 116B | 247B | 221B | 239B | 212B | 227B | 225B | 237B |
| Operating Income | -3.74B | -1.83B | 18.9M | -25.9B | -9.20B | -81.7B | -98.3B | -79.5B | -4.03B | 15.1B | 25.4B |
| EBITDA | - | 4.45B | 2.27B | -21.7B | 16.5B | -121B | -116B | -64.0B | 122B | 82.8B | 52.0B |
| Net Income | 266B | 652M | -3.72B | -22.5B | -19.2B | -70.9B | -102B | -59.6B | 63.0B | 10.9B | 2.81B |
| EPS | - | 58 | -346 | -1,989 | -1,699 | -6,278 | -9,064 | -5,277 | 5,582 | 947 | 244 |
| Balance Sheet | |||||||||||
| Total Assets | 204B | 275B | 265B | 806B | 799B | 921B | 863B | 877B | 855B | 803B | 791B |
| Total Liabilities | 97.2B | 100B | 101B | 485B | 494B | 737B | 693B | 707B | 601B | 457B | 434B |
| Shareholders' Equity | 105B | 173B | 164B | 138B | 123B | 53.3B | 11.8B | 39.0B | 134B | 169B | 174B |
| Cash & Short-term Investments | 54.8B | 34.5B | 33.6B | 104B | 126B | 175B | 99.0B | 71.2B | 79.3B | 76.6B | 71.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 46.6B | -2.19B | 6.23B | 14.3B | 8.24B | -30.5B | -74.6B | -57.8B | 17.3B | 26.9B | 19.7B |
| Capital Expenditure | 42.1B | 2.08B | 3.14B | 9.36B | 18.1B | 17.2B | 12.7B | 19.5B | 15.6B | 17.9B | 14.8B |
| Free Cash Flow | - | -4.43B | 3.03B | -465M | -14.8B | -53.3B | -95.7B | -77.3B | 1.72B | 8.97B | 4.86B |
| Ratios | |||||||||||
| ROE | 253.9% | 0.4% | -2.3% | -16.3% | -15.6% | -132.9% | -866.4% | -152.9% | 47.1% | 6.5% | 1.6% |
| ROA | 130.3% | 0.2% | -1.4% | -2.8% | -2.4% | -7.7% | -11.9% | -6.8% | 7.4% | 1.4% | 0.4% |
| Net Profit Margin | 652.4% | 1.6% | -7.9% | -7.7% | -3.2% | -12.0% | -15.2% | -9.3% | 9.9% | 1.8% | 0.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ildong Holdings Co Ltd dividends
- Dividend yield
- 0.09%
- Forward dividend
- 100.00 KRW
- Payout ratio
- 0.6%
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 60.2M | 5.21 | 0.6% |
| 2024 | KRW 1.21B | 107 | 1.9% |
| 2023 | KRW 1.38B | 122 | - |
| 2022 | KRW 1.31B | 116 | - |
| 2021 | KRW 1.19B | 105 | - |
| 2020 | KRW 1.09B | 97 | - |
| 2019 | KRW 2.08B | 184 | - |
| 2018 | KRW 2.09B | 195 | - |
| 2017 | KRW 1.07B | 95 | 164.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Mar 5, 2020.
Who owns Ildong Holdings Co Ltd
- Insiders 46.59%
- Institutions 0.01%
- Public & others 53.40%
- Shares outstanding 11.5M
- Free float 6.99M
Ildong Holdings Co Ltd company profile
- Company name
- Ildong Holdings Co Ltd
- Ticker
- 000230.KO
- ISIN
- KR7000230003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 136
- Fiscal year end
- December
- Address
- 2, Baumoe-ro 27-gil, Seoul, South Korea, 06752
- Phone
- 82 2 526 3114
- Website
- ildongholdings.co.kr
About Ildong Holdings Co Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, the company distributes medical devices, quasi drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products through online; and manufactures original and generic prescription drugs. Further, it offers probiotics; pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions; and engages in advertising business. The company was formerly known as Ildong Pharmaceutical Co., Ltd. and changed its name to Ildong Holdings Co., Ltd. in August 2016. Ildong Holdings Co., Ltd. was founded in 1941 and is headquartered in Seoul, South Korea.
Ildong Holdings Co Ltd management
3- Mr. Wonyoung YoonPresident · born 1938
- Mr. Woongseop YoonCEO & Vice Chairman · born 1967
- Mr. Yong-Sik KangManaging Director and Director · born 1960